Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCS-2 for LUTS Suggestive of BPH
NCT01002417Phase 3Completed
- Sponsor
- Health Ever Bio-Tech Co., Ltd.
- Start
- Jul 2010
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of MCS-2 in benign prostatic hyperplasia (BPH), sponsored by Health Ever Bio-Tech Co., Ltd.. Started Jul 2010; status: completed.
02
Drugs
MCS-2
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT01002417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01002417.